Insights

SynAct Pharma AB

Nasdaq Stockholm · LEI 549300RRYIEFEQ72N546· Fiscal year 2025

Staff cost per employee
Not disclosed
Employees
Not disclosed

Quick read

  • Operating loss of $11.4M in 2025.

Last 3 years

Revenue
$02024$02025
Operating income
-$8.8M2024-$11.4M2025

See the share price on Google Finance ↗

Investor metrics

2025
ROE
-65.1%
Debt-to-equity
29.5%
Equity ratio
77.2%

USD at SEK 10.18 per $1 (2026-11-20, ExchangeRate-API)

Staff costs from the annual report (wages, social charges, pensions) divided by the average number of employees. Usually higher than take-home pay.

audited consolidated financial statements · View the annual report (filings.xbrl.org)

Not investment advice. Figures come from public filings and may contain errors.